Sinopharm Group Co. Ltd. (SHTDY)
OTC: SHTDY
· Real-Time Price · USD
12.51
0.19 (1.50%)
At close: Aug 15, 2025, 3:55 PM
12.48
-0.27%
After-hours: Aug 15, 2025, 03:17 PM EDT
Sinopharm Income Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 590.35B | 598.32B | 596.57B | 591.69B | 591.63B | 570.07B | 552.15B | 546.15B | 533.4B | 528.38B | 521.05B | 510.09B | 501.77B | 482.28B |
Cost of Revenue | 543.16B | 550.17B | 548.06B | 543.1B | 542.58B | 521.7B | 504.71B | 500.52B | 488.28B | 483.54B | 477B | 466.06B | 458.1B | 440.04B |
Gross Profit | 47.18B | 48.15B | 48.51B | 48.58B | 49.05B | 48.36B | 47.43B | 45.63B | 45.12B | 44.84B | 44.05B | 44.04B | 43.67B | 42.25B |
Operating Income | 19.74B | 20.43B | 21.06B | 21.31B | 21.38B | 21.31B | 21.06B | 19.72B | 21.42B | 21.53B | 20.98B | 20.42B | 20.59B | 19.77B |
Interest Income | 622.38M | 1.54B | 1.65B | 1.64B | 2.42B | 2.35B | 2.6B | 3.31B | 3.16B | 3.33B | 3.15B | 2.82B | 2.85B | 2.62B |
Pretax Income | 18.24B | 19B | 19.51B | 19B | 19.43B | 19.05B | 18.56B | 17.35B | 17.29B | 17.36B | 17B | 17.11B | 17.1B | 16.41B |
Net Income | 8.65B | 8.88B | 9.05B | 8.77B | 8.94B | 8.69B | 8.53B | 7.91B | 7.87B | 7.97B | 7.76B | 7.93B | 7.87B | 7.59B |
Selling & General & Admin | 26.51B | 26.69B | 26.48B | 27.23B | 27.16B | 26.49B | 25.84B | 24.2B | 24.28B | 23.88B | 23.66B | 24.05B | 23.65B | 22.94B |
Research & Development | 663.8M | 688.63M | 713.46M | 663.05M | 612.65M | 578.31M | 543.97M | 459.65M | 375.32M | 355.96M | 336.59M | 307.79M | 278.99M | 264.4M |
Other Expenses | -127.27M | 575.59M | 9.36M | 37.67M | 20.68M | 20.68M | 20.68M | -7.63M | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 437.53B | 437.47B | 437.22B | 64.72B | 26.12B | 25.89B | 25.2B | 396.98B | 24.67B | 24.15B | 23.89B | 24.11B | 23.72B | 23.21B |
Interest Expense | 512.59M | 512.59M | 512.59M | 1.78B | 1.72B | 1.72B | 1.72B | 449.56M | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 17.52B | 17.54B | 17.47B | 17.45B | 17.38B | 17.06B | 16.72B | 15.69B | 15.61B | 15.48B | 15.44B | 15.95B | 15.49B | 14.89B |
Cost & Expenses | 569.97B | 576.92B | 574.55B | 569.43B | 568.7B | 547.59B | 529.91B | 525.17B | 512.96B | 507.69B | 500.89B | 490.16B | 481.82B | 463.25B |
Income Tax Expense | 4.23B | 4.4B | 4.5B | 4.4B | 4.42B | 4.32B | 4.22B | 3.99B | 4.03B | 4.03B | 3.94B | 3.79B | 3.78B | 3.59B |
Shares Outstanding (Basic) | 624.13M | 623.6M | 623.6M | 623.6M | 623.06M | 623.66M | 629.14M | 622.5M | 625.91M | 620.82M | 627.27M | 622.73M | 624.6M | 623.67M |
Shares Outstanding (Diluted) | 624.13M | 623.6M | 623.6M | 623.6M | 623.06M | 623.66M | 629.14M | 622.5M | 625.91M | 620.82M | 627.27M | 620.99M | 624.6M | 623.67M |
EPS (Basic) | 13.85 | 14.25 | 14.50 | 14.05 | 14.30 | 13.85 | 13.60 | 12.65 | 12.60 | 12.80 | 12.45 | 12.35 | 12.70 | 12.25 |
EPS (Diluted) | 13.85 | 14.25 | 14.50 | 14.05 | 14.30 | 13.85 | 13.60 | 12.65 | 12.60 | 12.80 | 12.45 | 12.35 | 12.70 | 12.30 |
EBITDA | 22.29B | 23.08B | 23.69B | 23.89B | 24.4B | 24.32B | 24.04B | 22.7B | 23.35B | 23.42B | 22.84B | 22.25B | 22.41B | 21.49B |
EBIT | 20.67B | 21.5B | 22.13B | 21.6B | 22.11B | 22.04B | 21.79B | 21.22B | 21.42B | 21.53B | 20.98B | 20.42B | 20.59B | 19.77B |
Depreciation & Amortization | 2.12B | 2.08B | 2.06B | 2.05B | 2.02B | 2B | 1.98B | 1.95B | 1.92B | 1.89B | 1.86B | 1.83B | 1.81B | 1.73B |